The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
Open accessPublished version of a preprint
Abstract
C o r r e s p o n d e n c e Protection against the Omicron Variant from Previous SARS-CoV-2 InfectionTo the Editor: Natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits strong protection against reinfection with the B.1.1.7 (alpha), 1,2 B.1.351(beta), 1 and B.1.617.2 (delta) 3 variants.However, the B.1.1.529(omicron) variant harbors multiple mutations that can mediate immune evasion.We estimated the effectiveness of previous infection in preventing symptomatic new cases caused by omicron and other SARS-CoV-2 variants in Qatar.In this study, we extracted data regarding coronavirus disease 2019 (Covid-19) laboratory testing, vaccination, clinical infection data, and related demographic details from the national SARS-CoV-2 databases, which include all results of polymerase-chain-reaction (PCR) testing, vaccinations, and hospitalizations and deaths for Covid-19 in Qatar since the start of the pandemic.The effectiveness of previous SARS-CoV-2 infection in preventing reinfection was defined as the proportional reduction in susceptibility to infection among persons who had recovered from infection as compared with those who had not been infected.4 Previous SARS-CoV-2 infection was defined as a positive result on PCR assay at least 90 days before a new positive PCR finding.4 We used a test-negative, case-control study design to assess the effectiveness of previ-
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accordingly, previous infections in this study were considered to be due to variants other than omicron, since they occurred before the omicron wave in Qatar.”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [2]
In the citing paper
“Of these specimens, 300 (95.2%) were confirmed to be omicron infections and 15 (4.8%) to be delta (or B.1.617.2)1 infections.”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [2]
In the citing paper
“These findings are explained by the short-lived protection of primary-series vaccination against omicron infections3,27 and the more durable protection from natural infection,2,28 as confirmed by the additional analysis of protection as a function of time after previous infection or vaccination (Figure 3).”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [2]
In the citing paper
“The results confirmed other findings that we reported recently, including a protection of approximately 50% for previous infection against reinfection with BA.1,2 a protection of approximately 50% for mRNA boosters as compared with primary series,4 and the finding that mRNA vaccines have negligible effectiveness against omicron infection 6 or more months after the second dose.3”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [2]
In the citing paper
“Extensive sensitivity and additional analyses were conducted to investigate effects of potential bias in our earlier studies that used similar methods. These included different adjustments and controls in the analysis and different study inclusion and exclusion criteria to investigate whether effectiveness estimates could have been biased.12,22 These analyses showed consistent findings.2,3,12,17,2”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [2]
In the citing paper
“The large Omicron-wave exponential-growth phase in Qatar started on December 19, 2021 and peaked in mid-January, 20222–5.”
From Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar (2022) · cites this paper as [3]
In the citing paper
“One study estimates a protection through previous infection of 92% against Delta and 56% against Omicron. 31”
From Vaccine mandates for healthcare workers beyond COVID-19 (2023) · cites this paper as [31]
In the citing paper
“Now, prior infection does not offer the same level of protection against Omicron as against Delta.”
From Vaccine mandates for healthcare workers beyond COVID-19 (2023) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rothman, K. J., Greenland, S., & Lash, T. L. (1998) · Cited by 2,096
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
Abu-Raddad, L. J., Chemaitelly, H., & Butt, A. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2104974 · Cited by 899
Self-citationWaning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Chemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114114 · Cited by 831
Self-citationAnalysis of matched case-control studies
Pearce, N. E. (2016) · BMJ · doi:10.1136/bmj.i969 · Cited by 774
The test-negative design for estimating influenza vaccine effectiveness
Jackson, M. L., & Nelson, J. C. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.053 · Cited by 510
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
Tang, P., Hasan, M. R., Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., AlMukdad, S., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01583-4 · Cited by 450
Self-citationChemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Hasan, M. R., Malek, J. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01446-y · Cited by 386
Self-citation(2021) · doi:10.1016/j.eclinm.2021.100861 · Cited by 201
Self-citationAbu-Raddad, L. J., Chemaitelly, H. S., Malek, J. A., Ahmed, A. A., Mohamoud, Y. A., Younuskunju, S., Ayoub, H. H., Kanaani, Z. A., Al‐Khal, A., Al‐Kuwari, E., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1846 · Cited by 176
Self-citationCOVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in Qatar
Saththasivam, J., El-Malah, S. S., Gomez, T., Jabbar, K. A., Remanan, R., Krishnankutty, A. K., Ogunbiyi, O. O., Rasool, K., Ashhab, S., Rashkeev, S. N., et al. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.145608 · Cited by 150
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 428
Lozano‐Rodríguez, R., Terrón‐Arcos, V., Montalbán-Hernández, K. M., Casalvilla‐Dueñas, J. C., Bergón-Gutiérrez, M., Pascual‐Iglesias, A., Quiroga, J. V., Aguirre, L. A., de Diego, R. P., Vela, C., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.869 · Cited by 3
Diem, G., Jäger, M., Dichtl, S., Bauer, A., Lass‐Flörl, C., Reindl, M., Wilflingseder, D., & Posch, W. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.05163-22 · Cited by 3
Course and clinical severity of the SARS-CoV-2 Omicron variant infection in Tianjin, China
Ren, Y., Shi, L., Xie, Y. F., Wang, C., Zhang, W., Wang, F., Sun, H., Huang, L., Wu, Y., Xing, Z., et al. (2023) · Medicine · doi:10.1097/md.0000000000034669 · Cited by 3
Chotpitayasunondh, T., Fisher, D. A., Hsueh, P., Lee, P., Crespo, K. A. N., & Ruxrungtham, K. (2022) · International Journal of Translational Medicine · doi:10.3390/ijtm2030024 · Cited by 3
Covid-19 Pandemic and Its Socio-economic Impact on India
-, S. R. (2024) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2024.v06i01.12222 · Cited by 3
Expert Review of Global Real-World Vaccine Effectiveness Against SARS-CoV-2Preprint
Chuenkitmongkol, S., Solante, R., Burhan, E., Chariyalertsak, S., Chiu, N., DO-VAN, D., Husin, M., Hwang, K., Kiertiburanakul, S., Kulkarni, P. S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1575499/v3 · Cited by 3
Farooq, F., Oakley, E. M., Kerchner, D., Kim, J. Y. H., Akelo, V., Barr, B. A. T., Bevilacqua, E., Bracero, N. J., Gil, M. D. M., Delgado‐López, C., et al. (2023) · medRxiv · doi:10.1101/2023.04.03.23287260 · Cited by 3
Jacobs, M. B., Clark, A. E., Goldhaber, N. H., Valentine, H. D., Rivera, A., Ngo, T., Barber, T., Holmes, J., Manfredi, B., Garretson, A. F., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae622 · Cited by 2
Poolchanuan, P., Matsee, W., Dulsuk, A., Phunpang, R., Runcharoen, C., Boonprakob, T., Hemtong, O., Chowplijit, S., Chuapaknam, V., Siripoon, T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-98627-3 · Cited by 2
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127556 · Cited by 2
Self-citationChemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11410-7 · Cited by 2
Self-citationKim, T.-H., Bae, S., & Myoung, J. (2025) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2507.07040 · Cited by 2
Su, S., Jiang, Z., Shi, L., Liu, X., Zhang, Z., Mei, H., Gao, N., Wu, S., Li, M., Zhang, X., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04322-5 · Cited by 2
Martins, J., Vimalanathan, S., ROAD, J. D., & Miller, C. C. (2026) · Viruses · doi:10.3390/v18010091 · Cited by 2
Gim, H., Lee, S., Seo, H., Park, Y., & Chun, B. C. (2023) · Vaccines · doi:10.3390/vaccines11091408 · Cited by 2
Lee, S., Zabinsky, Z. B., Wasserheit, J. N., Ross, J. M., Chen, S., & Liu, S. (2023) · AJPM Focus · doi:10.1016/j.focus.2023.100155 · Cited by 2
Pre-vaccination seroprevalence of SARS-CoV-2 antibodies in the Volta Region, Ghana
Aninagyei, E., Ayivor-Djanie, R., Gyamfi, J., Aboagye, M. E., Kpeli, G. S., Ampofo, W., Gyapong, J. O., & Duedu, K. O. (2024) · IJID Regions · doi:10.1016/j.ijregi.2024.01.007 · Cited by 2
Petrie, J. G., Pattinson, D., King, J. P., Neumann, G., Guan, L., Jester, P. J., Rolfes, M. A. R., Meece, J. K., Kieke, B. A., Belongia, E. A., et al. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae125 · Cited by 2
Understanding the COVID-19 pandemic through bayesian spatio-temporal modeling of several outcomes
Rodriguez-Idiazabal, L., Martínez‐Beneito, M. A., Quintana, J. M., García-Asensio, J., Legarreta, M. J., Larrea, N., & Barrio, I. (2025) · Spatial and Spatio-temporal Epidemiology · doi:10.1016/j.sste.2025.100737 · Cited by 2
Immunity Against the Omicron Variant From Vaccination, Recovery, or Both
Gandhi, M. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac172 · Cited by 2
Racial/Ethnic Variances in COVID-19 Inoculation among Southern California Healthcare Workers
Dubov, A., Distelberg, B. J., Abdul‐Mutakabbir, J. C., Peteet, B. J., Roberts, L. R., Montgomery, S., Rockwood, N., Patel, P., SHOPTAW, S. J., & Chrissian, A. A. (2022) · Vaccines · doi:10.3390/vaccines10081331 · Cited by 2
Understanding the immunological landscape of England during SARS-CoV2 Omicron variant wave
Shingleton, J., Dyke, S., Herrick, A., & Finnie, T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264870 · Cited by 2
Controversies Concerning Emergency Tracheal Intubation in Patients with COVID-19
Jiang, B., Wei, H., & Feng, Y. (2023) · Journal of Anesthesia and Translational Medicine · doi:10.58888/2957-3912-20230207-3 · Cited by 2
Lim, S. H., Choi, S. H., Kim, J. Y., Kim, B., Kim, H. J., Kim, S. H., Kim, C. K., Park, S. K., & Yun, J. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e139 · Cited by 2
Lisson, Y., Marmor, A., Gomez, A., Hall, R. N., Parry, A. E., Wright, R., & Lal, A. (2023) · Communicable Diseases Intelligence · doi:10.33321/cdi.2023.47.22 · Cited by 2
Osman, K., Mundodan, J. M., Chowdhury, J., Ravi, R. P., Baaboura, R., Albuquerque, J., Riaz, B., Emran, R. Y., Batoul, K., Esameldin, A. M., et al. (2023) · Vaccines · doi:10.3390/vaccines11101522 · Cited by 2
Evaluating the risk of SARS-CoV-2 reinfection with the Omicron or Delta variant in Wales, UK
Postans, M., Pacchiarini, N., Song, J., Cottrell, S. L., Williams, C., Beazer, A., Moore, C., Connor, T. R., & Williams, C. J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309645 · Cited by 2
Planning and adjusting the COVID-19 booster vaccination campaign to reduce disease burden
Domenico, L. D., Goldberg, Y., & Colizza, V. (2024) · Infectious Disease Modelling · doi:10.1016/j.idm.2024.09.002 · Cited by 3
Frieswijk, K., Zino, L., & Cao, M. (2022) · European Control Conference (ECC) · doi:10.23919/ecc55457.2022.9838287 · Cited by 2
The genomic and clinical features of the COVID-19 Omicron variant: a narrative review
Hertanto, D. M., Sutanto, H., Lusida, M. I., Kuntaman, K., & Santoso, D. (2022) · F1000Research · doi:10.12688/f1000research.110647.1 · Cited by 2
Kahlert, C. R., Güsewell, S., & Kohler, P. P. (2022) · doi:10.5281/zenodo.7149075 · Cited by 2
Chau, N. V. V., Nguyet, L. A., Dung, N. T., Quang, V. M., Truong, N. T., Toan, L. M., Hung, L. M., Man, D. N. H., Khoa, D. B., Phong, N. T., et al. (2022) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.22-0434 · Cited by 2
Bourdas, D. I., Bakirtzoglou, P., Travlos, A. K., Andrianopoulos, V., & Zacharakis, E. (2023) · Vaccines · doi:10.3390/vaccines11091431 · Cited by 2
Grint, D. J., Wing, K., Gibbs, H. P., Evans, S. J. W., Williamson, E., Bhaskaran, K., McDonald, H. I., Walker, A. J., Evans, D., Hickman, G., et al. (2022) · medRxiv · doi:10.1101/2022.05.03.22274602 · Cited by 2
Patterns in Repeat Reinfections: Pre and Post Omicron EmergencePreprint
Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Yassine, H. M., Thani, A. A. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2023) · medRxiv · doi:10.1101/2023.06.29.23292041 · Cited by 2
Self-citationSukik, L., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-002718 · Cited by 1
Self-citationNarum, S., Stalder, T., Ridenhour, B. J., & Coats, E. R. (2025) · Water Research · doi:10.1016/j.watres.2025.123818 · Cited by 1
SARS-CoV-2 infection and vaccination elicit distinct pharyngeal mucosal B cell responses in children
Xu, Q., Shi, L., Wang, L., Cheung, F., Kotekar, A., Koroleva, G., Rice, E., Apps, R., Lack, J., Martens, C., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72996-3 · Cited by 1
Timeline of the pandemic: epidemiology, global spread, variants and waves
Liu, Y.-X., Luo, J.-Y., Liu, R., Li, Y., & Guan, W. (2024) · European Respiratory Society eBooks · doi:10.1183/2312508x.10018823 · Cited by 1
Hurst, J. R., Naghibosadat, M., Budowski, P., Li, J., Samaan, P., Budiman, F., Kurtesi, A., Qi, F., Menon, H., Krishnan, R. G., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0314061 · Cited by 1
Gonzalez-Carmona, M. A., Schmitz, A. M., Berger, M., Baier, L. I., Gorny, J. G., Sadeghlar, F., Anhalt, T., Zhou, X., Zhou, T., Mahn, R., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413613 · Cited by 1
Hong, W., Du, N., Zhang, Y., Jiang, J., Sun, J., Wang, R., & Chen, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-25459-6 · Cited by 1
Fu, Y., Feng, Z., Erickson, S. A., Halfmann, P., Li, L., Chervin, J. C., Troxell, C. A., Sun, J., Yasuhara, A., Changrob, S., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117137 · Cited by 2
Healthy vaccinee effect did not bias COVID-19 vaccine effectiveness estimates
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2026) · Communications Health · doi:10.1038/s44528-026-00006-5 · Cited by 1
Self-citationHumoral Response after SARS-CoV-2 Vaccination in Prostate Cancer Patients
Błaszczuk, A., Sikora, D., Kiś, J., Stępień, E., Drop, B., & Polz‐Dacewicz, M. (2023) · Vaccines · doi:10.3390/vaccines11040770 · Cited by 2
Novellis, D. D., Folliero, V., Giudice, V., Pezzullo, L., Sanna, G., Fontana, R., Guariglia, R., Zannella, C., Mettivier, L., Ferrara, I., et al. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01223-w · Cited by 1
Berenguer, J., Calvo-Alcántara, M. J., Álvaro‐Meca, A., Estévez, J. C., Basanta, M., Ruiz, S., Mataix, A. L., Bienzobas, C., Cosano, L. G., Silva, A. P., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad635 · Cited by 1
Effect of SARS-CoV-2 Infection on IVF/ICSI-ET Outcomes: A Propensity Score-matched Cohort Study
Li, Y., Ding, X., Luo, D. L., Li, T., Liu, L., Li, B., Chen, C., Liu, Y., & Ding, H. (2023) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog5012278 · Cited by 1
Li, C., Zhou, T., Zhang, P., He, J., & Liu, Y. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1394762 · Cited by 1
Risk of COVID-19 reinfection and vaccine breakthrough infection, Madera County, California, 2021
Nguyen, M., Paul, E., Mills, P. K., & Paul, S. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae308 · Cited by 1
La, Y., Oh, W. S., Kim, C., Lim, M.-N., & Jeon, Y. D. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10585-3 · Cited by 1
Zhao, C., Liu, L., Ge, Z., Wang, J., Ranran, W., Jiang, Z., Tian, D., & Chen, Z. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11398-0 · Cited by 1
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331654 · Cited by 1
Self-citationPoolchanuan, P., Tiacharoen, V., Dulsuk, A., Phunpang, R., Runcharoen, C., Boonprakob, T., Hemtong, O., Chowplijit, S., Chuapaknam, V., Siripoon, T., et al. (2026) · Scientific Reports · doi:10.1038/s41598-025-33388-7 · Cited by 1
El enigma del coronavirus – El avance de la variante ómicron – La deltacron
Romero, J. P. (2022) · Revista Peruana de Ginecología y Obstetricia · doi:10.31403/rpgo.v68i2388 · Cited by 1
Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals
Kurshan, A., Snell, L. B., Prior, L., Tam, J. C. H., Graham, C., Thangarajah, R., Edgeworth, J. D., Nebbia, G., & Doores, K. J. (2023) · Oxford Open Immunology · doi:10.1093/oxfimm/iqac012 · Cited by 1
Viral Mitigation: Weak Theoretical Underpinnings
Karadimas, P. (2023) · Studies in Public Choice · doi:10.1007/978-3-031-24967-9_2 · Cited by 1
Protection from infection and reinfection due to the Omicron BA.1 variant in care homes
Choudhry, S., Rowland, T. A. J., McClelland, K., Renz, E., Iyanger, N., Chow, J. Y., Aiano, F., Ladhani, S. N., Jeffery-Smith, A., Andrews, N. J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1186134 · Cited by 1
Zhu, Y., Gu, J., Qiu, Y., & Chen, S. X. (2023) · The Annals of Applied Statistics · doi:10.1214/23-aoas1764 · Cited by 1
Covid19Vaxplorer: A free, online, user-friendly COVID-19 vaccine allocation comparison tool
Trejo, I., Hung, P.-Y., & Matrajt, L. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002136 · Cited by 1
Ma, Y., Zhang, Q., Shan, Z., Chen, Y., Chen, Y., Pan, X., & Huang, Y. (2024) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-024-06657-y · Cited by 1
A Southeast Asia Expert Review of Global Real-World Vaccine Effectiveness Against SARS-CoV-2Preprint
Chuenkitmongkol, S., Solante, R., Burhan, E., Chariyalertsak, S., Chiu, N., DO-VAN, D., Husin, M., Hwang, K., Kiertiburanakul, S., Kulkarni, P. S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1575499/v2 · Cited by 1
Risk of SARS-CoV-2 reinfection is time- and variant-dependant, France, January 2021 to August 2022Preprint
Auvigne, V., Schaeffer, J., Boudon, T., Tamandjou, C. R. T., Figoni, J., du Châtelet, I. P., & Bernard-Stoecklin, S. (2022) · medRxiv · doi:10.1101/2022.11.09.22282113 · Cited by 1
Jurdi, A. A., Morená, L., & Riella, L. V. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.01.009 · Cited by 1
Contact structure and population immunity shape the selective advantage of emerging variantsPreprint
Simin, P. T., Taube, J. C., Vergu, E., Opatowski, L., Bansal, S., & Poletto, C. (2025) · medRxiv · doi:10.1101/2025.11.07.25339691 · Cited by 1
A Southeast Asia Expert Review of Global Real-World Vaccine Effectiveness Against SARS-CoV-2Preprint
Chuenkitmongkol, S., Solante, R., Burhan, E., Chariyalertsak, S., Chiu, N., DO-VAN, D., Husin, M., Hwang, K., Kiertiburanakul, S., Kulkarni, P. S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1575499/v1
The Case for Acquired Immunity as a Strategy to Thwart SARS-CoV-2 Virus Infection
Kieber‐Emmons, T. (2022) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2022.29008.tke
Protection Due to Previous SARS-CoV-2 Infection
Jolobe, O. M. P. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2205555
Reinfection risk and vaccination effectiveness against OmicronPreprint
Du, J., Zhao, Y., & He, D. (2022) · Research Square · doi:10.21203/rs.3.rs-1535365/v1
Schützt eine frühere SARS-CoV-2-Infektion vor einer erneuten Infektion?
Metzger, L. (2022) · Pneumologie · doi:10.1055/a-1807-1402
Reinfection risk and vaccination effectiveness against OmicronPreprint
Du, J., Zhao, Y., & He, D. (2022) · Research Square · doi:10.21203/rs.3.rs-1535365/v2
Neutralizing Antibody to Omicron BA.1, BA.2 and BA.5 in COVID-19 PatientsPreprint
Linderman, S. L., Lai, L., Gamarra, E. L. B., Mohr, N. M., Gibbs, K. W., Steingrub, J. S., Exline, M. C., Shapiro, N. I., Frosch, A. E. P., Qadir, N., et al. (2022) · medRxiv · doi:10.1101/2022.08.21.22278552
Do the Co-Morbid Conditions are Risk Factors for COVID-19 Patients? A View in a Tertiary Care Center
Murugan, C. K. (2022) · Annals of Case Reports · doi:10.29011/2574-7754.100931
Witberg, G., & Richter, I. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.09.010
Immunity Acquired From the First Wave of COVID-19 Against Reinfections Up to Omicron Predominance
Lan, F., Kasteler, S. D., Sidossis, A. C., Iliaki, E. F., Buley, J., Nathan, N., Osgood, R. A., Bruno‐Murtha, L. A., & Kales, S. N. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.11.002
Collarino, R., Vauloup‐Fellous, C., Allemang‐Trivalle, A., Mouna, L., Baudouin, É., Keravec, H., Neiss, M., Bouchareb, S., Bessai, C., Sanchez-Tamayo, J., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac613
SARS-CoV-2’NİN SÜREGELEN EVRİMİ: PANDEMİNİN SONUNA NE KADAR YAKINIZ?
Kilbaş, E. P. K., & Altındiş, M. (2022) · JOURNAL OF BIOTECHNOLOGY AND STRATEGIC HEALTH RESEARCH · doi:10.34084/bshr.1200144
A Study on The Efficacy of Vaccination in Elderly Patients with Breakthrough COVID-19 Infection
Choi, S., Choi, Z., Ha, C., Lee, H.-J., & Kim, C. M. (2022) · 대한임상노인의학회지 · doi:10.15656/kjcg.2022.23.2.115
Mueller, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-18903-6_12
Rehospitalization Incidence in COVID-19 Reinfection: A Retrospective Cohort Study
Elattar, M. A., Gad, S. A., Elgamal, A. N., Beltagy, E. M., Elsheikh, T. S., Elfeky, K. E., ela-zziz, A. M. A., & Elmsri, H. Y. (2023) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2023.285044
Two-Year Cohort Study of SARS-CoV-2, Verona, Italy, 2020‒2022
Bisoffi, Z., Santis, N. D., Piubelli, C., Deiana, M., Perandin, F., Girardi, P., Heller, L., Alba, N., Pomari, C., & Guerriero, M. (2023) · Emerging infectious diseases · doi:10.3201/eid2904.221268
SARS-CoV-2 During Omicron Variant Predominance Among Infants Born to People With SARS-CoV-2
Gosdin, L. K., Chang, D. J., Olsen, E. O., Lewis, E. L., Wingate, H., Ojo, K. D., Shephard, H. M., Sokale, A., Mobley, E. L., Delgado‐López, C., et al. (2023) · PEDIATRICS · doi:10.1542/peds.2022-061146
Comparative Analysis of SARS-CoV-2 Variants Across Three Waves in India
Agarwal, K., & Parekh, N. (2023) · Advances in health sciences research/Advances in Health Sciences Research · doi:10.2991/978-94-6463-164-7_9
Carvalho, E., Pina, B. D. C., Neto, R., Lima, W., Bandeira, V., & Carvalho, L. (2023) · Advances in Infectious Diseases · doi:10.4236/aid.2023.132028
Holdenrieder, S., Ferreira, C. E. D. S., Izopet, J., Theel, E. S., & Wieser, A. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1290402
Prior Infection Reduces Omicron COVID-19 Severity in Solid Organ Transplant Recipients
Boan, P. (2024) · Transplantation · doi:10.1097/tp.0000000000004905
Chew, C. K., Wang, R., Bavanandan, S., Zainudin, N., Zhao, X., Ahmed, S., Nair, D., Hou, L., Yahya, R., Ch'ng, S. S., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4759168
Montecalvo, M. A., Visintainer, P., Drugge, E. D., Kowalski, K., Raffa, R., McKenna, D. F., Moronta, C., & Wormser, G. P. (2024) · Vaccines · doi:10.3390/vaccines12030327
Schlosser, T., Krasselt, M., Elsing, L., Hecker, M., Holler, B., & Hoffmeister, A. (2024) · Autoimmune Diseases · doi:10.1155/2024/6627035
Rajunitrigo, R., Muryanto, I., Mahkota, R., Siregar, F. M., Elvita, N., Malfasari, E., Basra, M. U., & Marwanty, M. (2024) · Jurnal Berkala Epidemiologi · doi:10.20473/jbe.v12i22024.134-142
Yang, S., Xin, H., Lang, X., Jin, H., Cui, X., Li, L., Ye, C., Qin, Y., Li, Y., Cowling, B. J., et al. (2024) · Transboundary and Emerging Diseases · doi:10.1155/2024/9533861
Mostafa, H. H., & Pinsky, B. A. (2023) · ClinMicroNow · doi:10.1002/9781683674849.mcm0093
Mostafa, H. H., & Pinsky, B. A. (2023) · ClinMicroNow · doi:10.1002/9781683670438.mcm0093
Shi, Y., Sun, X., Yu, Z., Dai, D., Guo, H., Mei, L., Dai, J., & Jiang, L. (2025) · Natural Product Communications · doi:10.1177/1934578x251327922
Ahmed, M. N., Habib, U. S. A., Abdallah, A., Emara, M. M., Pain, A., Thani, A. A. A., Nasrallah, G. K., Yassine, H. M., & Al-Khatib, H. A. (2025) · Journal of General Virology · doi:10.1099/jgv.0.002108
Self-citationEscobar-Agreda, S., Araujo-Castillo, R. V., Pampa-Espinoza, L., Valencia, J. S., & Solari, L. (2025) · Pathogens and Immunity · doi:10.20411/pai.v10i2.760
Englund, J. A., Kim, Y.-J., McIntosh, K., Maurice, A. D. S., Freeman, M. C., & Denison, M. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00201-6
Metadata
- Authors
- Altarawneh, H. N., Chemaitelly, H., Hasan, M. R., Ayoub, H. H., Qassim, S., AlMukdad, S., Coyle, P., Yassine, H. M., Al-Khatib, H. A., Benslimane, F. M., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G. K., Al-Kuwari, M. G., Butt, A. A., Al-Romaihi, H. E., Al-Thani, M. H., Al-Khal, A., Bertollini, R., Tang, P., & Abu-Raddad, L. J.
- Affiliations
- Weill Cornell Medical College in Qatar (QA)
- Sidra Medicine, Doha, Qatar
- Qatar University (QA)
- Hamad Medical Corporation (QA)
- Primary Health Care (QA)
- Ministry of Public Health (QA)
- Corresponding author
- Abu-Raddad, Laith J.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-03-31
- Volume
- 386
- Issue
- 13
- Pages
- 1288-1290
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8849180
- OpenAlex
- W4211118466
- Cited by
- 445
- References
- 24
- Citations by year
- 2026: 10 · 2025: 32 · 2024: 66 · 2023: 129 · 2022: 208
- FWCI
- 53.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- medRxiv (acceptedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Qatar University QSpace (Qatar University) (submittedVersion)
- Funders
- Qatar Genome Program and Qatar University Biomedical Research Center
- Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core at Weill Cornell Medicine–Qatar
- Qatar Ministry of Public Health; Hamad Medical Corporation; and Sidra Medicine
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- Omicron variant, SARS-CoV-2, natural immunity, prior infection, reinfection prevention, immune evasion, symptomatic COVID-19, test-negative design, Qatar
- MeSH terms
- COVID-19, SARS-CoV-2, Humans, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
